Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;82(11):1229-1234.
doi: 10.1007/s40265-022-01749-5.

Mosunetuzumab: First Approval

Connie Kang  1
Affiliations
Review

Mosunetuzumab: First Approval

Connie Kang. Drugs. 2022 Jul.

Abstract

Mosunetuzumab (Lunsumio®), an anti-CD20/CD3 T-cell engaging bispecific antibody, is being developed by Roche for the treatment of relapsed or refractory follicular lymphoma. Mosunetuzumab was recently conditionally approved in the EU for the treatment of relapsed or refractory follicular lymphoma in adults who have received at least two prior systemic therapies. This article summarizes the milestones in the development of mosunetuzumab leading to this first approval for relapsed or refractory follicular lymphoma.

PubMed Disclaimer

References

    1. Dreyling M, Ghielmini M, Rule S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(3):298–308.
    1. Roche. Lunsumio (mosunetuzumab): EU prescribing information; 2022. https://www.ema.europa.eu . Accessed 5 Jul 2022.
    1. European Medicines Agency. Lunsumio; 2022. https://www.ema.europa.eu . Accessed 5 Jul 2022.
    1. Roche. Product development portfolio; 2022. https://www.roche.com/solutions/pipeline . Accessed 5 Jul 2022.
    1. Biogen. Biogen exercises option to participate in the development and commercialization of a late-stage bispecific antibody [media release]. 1 Feb 2022. https://investors.biogen.com .

LinkOut - more resources